Initial pharmacologic therapy for acute upper gastrointestinal bleeding
Initiated medication depends on suspected etiology. For suspected nonvariceal upper gastrointestinal bleeding (NVUGIB), prokinetic therapy with erythromycin before endoscopy is suggested, and a high-dose intravenous proton pump inhibitor (PPI) strategy is recommended after successful endoscopic hemostasis for bleeding ulcers. [1] For suspected acute variceal hemorrhage in a cirrhotic patient, vasoactive therapy should be started as soon as variceal bleeding is suspected and before esophagogastroduodenoscopy (EGD). [3]
Nonvariceal upper gastrointestinal bleeding medication now
Prokinetic therapy before endoscopy:
- Erythromycin infusion is suggested before endoscopy in patients with upper gastrointestinal bleeding (UGIB). [1]
PPI therapy before endoscopy:
- Pre-endoscopic PPI therapy is not recommended or discouraged by the American College of Gastroenterology (ACG) because the panel could not reach a recommendation. [1]
- Pre-endoscopy high-dose intravenous PPI therapy can be considered to downstage endoscopic stigmata without delaying early endoscopy. [2]
Variceal hemorrhage medication now
Vasoactive therapy for suspected acute variceal hemorrhage:
- Octreotide is the most commonly used vasoactive agent and should be initiated as soon as variceal hemorrhage is suspected and before EGD. [3]
- Octreotide is administered as an initial intravenous bolus followed by an intravenous infusion for approximately 5 days even after bleeding is controlled (dosing schedule listed as 50 mcg bolus followed by 50 mcg/hour). [3]
- Terlipressin is an alternative vasoactive agent where available, with an initial dosing schedule followed by dose reduction once bleeding is controlled (dosing schedule listed). [3]
Antisecretory therapy after endoscopic hemostasis for bleeding ulcers
High-dose PPI therapy after successful endoscopic hemostasis is recommended:
- High-dose PPI therapy is recommended continuously or intermittently for 3 days after successful endoscopic hemostatic therapy of a bleeding ulcer. [1]
- High-dose PPI therapy followed by step-down to twice-daily PPI therapy is suggested for high-risk patients until 2 weeks after the index endoscopy. [1]
Post-endoscopy regimen selection principles
PPI therapy duration depends on endoscopic outcome and bleeding risk:
- A 3-day high-dose PPI course is used for patients with successful endoscopic hemostasis of a bleeding ulcer. [1]
- Extended twice-daily PPI therapy up to 2 weeks is used for selected high-risk patients. [1]
Common pitfall in “medications now” selection
Etiology misclassification leads to inappropriate pharmacologic therapy:
- Somatostatin-analogue therapy for NVUGIB is not recommended by ESGE for nonvariceal etiologies. [2]
- Vasoactive therapy is recommended for suspected acute variceal hemorrhage before endoscopy. [3]
Medication priorities by immediate clinical workflow
If endoscopy is imminent and NVUGIB is suspected:
- Erythromycin infusion before endoscopy is prioritized. [1]
- Pre-endoscopy high-dose intravenous PPI therapy may be considered without delaying endoscopy. [2]
If cirrhosis with suspected acute variceal hemorrhage is present:
- Vasoactive therapy (octreotide or terlipressin where available) is started immediately before EGD. [3]
Targeted end points of acute pharmacologic therapy
For suspected acute variceal hemorrhage, vasoactive therapy is intended to control bleeding before endoscopic confirmation and therapy. [3] For NVUGIB due to bleeding ulcers, high-dose PPI therapy after endoscopic hemostasis is intended to reduce rebleeding risk during the early post-hemostasis period. [1]